Suchergebnisse - "Kato, Eri T"

PubPharm (14)

1

Modifiers of the Risk of Diabetes for Long-Term Outcomes After Coronary Revascularization : CREDO-Kyoto PCI/CABG Registry

enthalten in: JACC. Asia | 2022

von Yamaji, K. | Shiomi, H. | Morimoto, T. | +153

2

Stent-Related Adverse Events as Related to Dual Antiplatelet Therapy in First- vs Second-Generation Drug-Eluting Stents

enthalten in: JACC. Asia | 2021

von Yoshikawa, Y. | Shiomi, H. | Morimoto, T. | +20

3

The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus

enthalten in: Diabetologia | 2021

von O'Donoghue, M. | Kato, E. | Mosenzon, O. | +15

4

The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus

enthalten in: Diabetologia | 2021

von O’Donoghue, M. | Kato, E. | Mosenzon, O. | +15

5

The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus

enthalten in: Diabetologia | 2021

von O’Donoghue, M. | Kato, E. | Mosenzon, O. | +15

6

The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus

enthalten in: Diabetologia | 2021

von O’Donoghue, M. | Kato, E. | Mosenzon, O. | +15

7

Response by Kato et al to Letter Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus"

enthalten in: Circulation | 2019

von Kato, E. | Sabatine, M. | Wiviott, S.

CommentOn: Circulation. 2019 Oct 29;140(18):e738-e739. - PMID 31657960

8

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes : an analysis from the DECLARE-TIMI 58 randomised trial

enthalten in: The lancet. Diabetes & endocrinology | 2019

von Mosenzon, O. | Wiviott, S. | Cahn, A. | +18

CommentIn: Lancet Diabetes Endocrinol. 2019 Aug;7(8):585-587. - PMID 31196816

9

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

enthalten in: Circulation | 2019

von Kato, E. | Silverman, M. | Mosenzon, O. | +20

CommentIn: Circulation. 2019 May 28;139(22):2537-2541. - PMID 30882236

10

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus

enthalten in: Circulation | 2019

von Zelniker, T. | Wiviott, S. | Raz, I. | +12

CommentIn: Kidney Int. 2019 Jul;96(1):8-10. - PMID 31229049